Neoplasms Clinical Trial
Official title:
A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics of CC-486 (Onureg®) in Subjects With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Adult Cancer Subjects
The purpose of this study is to evaluate the effect of moderate and severe liver impairment on the drug levels of oral azacitidine and the safety and tolerability of oral azacitidine in adult cancer participants. This study will also evaluate the safety and tolerability of intravenous/subcutaneous azacitidine in adult cancer participants.
n/a
| NCT number | NCT05209295 |
| Study type | Interventional |
| Source | Bristol-Myers Squibb |
| Contact | BMS Study Connect Contact Center www.BMSStudyConnect.com |
| Phone | 855-907-3286 |
| [email protected] | |
| Status | Not yet recruiting |
| Phase | Phase 1 |
| Start date | November 11, 2022 |
| Completion date | June 1, 2025 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
| Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
| Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
| Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
| Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT02292641 -
The Beyond TME Trial
|
N/A | |
| Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
| Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
| Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
| Not yet recruiting |
NCT05440240 -
Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture
|
Phase 4 | |
| Recruiting |
NCT03190811 -
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02909348 -
Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab
|
||
| Not yet recruiting |
NCT02806557 -
Profiling Neutrophil Counts in Patients on Chemotherapy
|
N/A | |
| Recruiting |
NCT02514512 -
Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking
|
Phase 1 | |
| Completed |
NCT02636426 -
Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study
|
Phase 1 | |
| Completed |
NCT01915576 -
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
|
Phase 1 | |
| Completed |
NCT01911936 -
A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors
|
Phase 1 | |
| Suspended |
NCT01562626 -
Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors
|
Phase 1/Phase 2 |